KYMR vs. PFE: Kymera Therapeutics vs. Pfizer Stock Comparison

Company Profile

Kymera Therapeutics (KYMR) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but KYMR is classified in Biotechnology while PFE is classified in Pharmaceuticals.

Pfizer (PFE) has more than two decades of public-market history since June 1, 1972, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Kymera Therapeutics (KYMR) has an aggressive beta of 2.00, indicating higher sensitivity to broad-market moves, while Pfizer (PFE) is defensive at 0.35 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Pfizer (PFE) is heavily traded at around 33.67M shares per day, whereas Kymera Therapeutics (KYMR) sees a more moderate 833.05K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Pfizer (PFE) reports 4.47%, ranking against industry peers normally.

Pfizer (PFE) at 6.34% retains a top-quartile share of revenue as profit, ahead of Kymera Therapeutics (KYMR) at 0.00%, which keeps about the industry-typical share.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Pfizer (PFE) reports 33.38%, ranking against industry peers normally.

Profitability Metrics

Growth

Both Kymera Therapeutics (KYMR) at -16.70% and Pfizer (PFE) at -1.65% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Only one side can be read here: Pfizer (PFE) reports EPS growth of -3.55%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Pfizer (PFE) at 1.42 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for PFE.

Kymera Therapeutics (KYMR) at 0.05 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Kymera Therapeutics (KYMR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Kymera Therapeutics (KYMR) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Pfizer (PFE) trades at 41.99 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Kymera Therapeutics (KYMR) at 110.00 prices above its industry range — a wide gap in sales valuation between them.

Pfizer (PFE) at 1.88 is valued about in line with its industry on P/B ratio, while Kymera Therapeutics (KYMR) at 6.96 carries an above-peer premium to book — KYMR is pricier on assets.

Valuation Metrics